Amy J. Spandau
Corporate Officer/Principal chez FREELINE THERAPEUTICS HOLDINGS PLC
Provenance du réseau au premier degré de Amy J. Spandau
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Subsidiary | Biotechnology | 19 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Amy J. Spandau via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| BECTON, DICKINSON AND COMPANY | Medical Specialties | Corporate Officer/Principal | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal General Counsel | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Administrative Officer | |
| ABEONA THERAPEUTICS INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Akin, Gump, Strauss, Hauer & Feld LLP
 Akin, Gump, Strauss, Hauer & Feld LLP Miscellaneous Commercial ServicesCommercial Services Akin Gump Strauss Hauer & Feld LLP provides legal services. The firm's areas of practice includes appellate, litigation, business and commercial litigation, dispute resolution, government contracts, internal investigations, labor and employment, oil and gas patent, trademark and copyright infringement, product liability and toxic tort securities litigation. The company was founded in 1971 and is headquartered in Washington, DC. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| LEXICON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
| AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Director of Finance/CFO | |
| TETRAPHASE PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of Aberdeen | College/University | Undergraduate Degree | |
| University of Salford | College/University | Undergraduate Degree | |
| Boston College | College/University | Undergraduate Degree | |
| Marshall University | College/University | Undergraduate Degree | |
| Meredith College | College/University | Masters Business Admin | |
| New York University | College/University | Undergraduate Degree | |
| Technical University of Denmark | College/University | Masters Business Admin | |
| Georgetown University | College/University | Undergraduate Degree Undergraduate Degree | |
| University College London | College/University | Corporate Officer/Principal | |
| The Open University | College/University | Doctorate Degree | |
| University of Copenhagen | College/University | Graduate Degree | |
| William & Mary School of Law | College/University | Graduate Degree | |
| SCHRÖDINGER, INC. | Packaged Software | Director/Board Member | |
| Loughborough University | College/University | Undergraduate Degree | |
New York State Bar Association
 New York State Bar Association Miscellaneous Commercial ServicesCommercial Services New York State Bar Association is a non-profit organization, which provides legal services and offers a membership program for lawyers. It also publishes an array of books, bar journals, law digest, and State Bar news. The company was founded in 1876 and is headquartered in Alban, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Veterans Administration Medical Center
 Veterans Administration Medical Center Hospital/Nursing ManagementHealth Services Veterans Administration Medical Center provides healthcare services. The private company is based in San Diego, CA. | Hospital/Nursing Management | Corporate Officer/Principal | |
The District of Columbia Bar
 The District of Columbia Bar Miscellaneous Commercial ServicesCommercial Services The District of Columbia Bar provides legal services. The private company is based in Washington. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Infectious Diseases Society of America
 Infectious Diseases Society of America Miscellaneous Commercial ServicesCommercial Services The Infectious Diseases Society of America is a non-profit company that provides clinical practice guidelines development and guideline panelists for infectious diseases. The company is based in Arlington, VA and has subsidiaries in the United States. The company specializes in antimicrobial stewardship and have established Antimicrobial Stewardship Centers of Excellence. The CEO of the company is Christopher Busky. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
The American Society for Clinical Pharmacology & Therapeutics
 The American Society for Clinical Pharmacology & Therapeutics Miscellaneous Commercial ServicesCommercial Services The American Society for Clinical Pharmacology & Therapeutics is a scientific and professional organization that serves the disciplines of clinical pharmacology and translational medicine. The non-profit company is based in Alexandria, VA. The CEO of the company is Sharon Swan. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| The New York Bar Foundation | Corporate Officer/Principal | ||
| Georgetown University Law Center | College/University | Graduate Degree | |
| Georgetown University School of Medicine | College/University | Doctorate Degree | |
| Yale School of Medicine | College/University | Doctorate Degree | |
Adicet Therapeutics, Inc.
 Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Pharmaceuticals: Major | Director/Board Member | |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Founder Director/Board Member Founder Director/Board Member | |
| PRAXIS PRECISION MEDICINES, INC. | Pharmaceuticals: Major | Director/Board Member | |
Auregen Biotherapeutics SA
 Auregen Biotherapeutics SA Packaged SoftwareTechnology Services Auregen Biotherapeutics SA develops three dimensional (3D) bioprinting technology for patients with rare disorders. The company is headquartered in Geneva, Switzerland. | Packaged Software | Chief Tech/Sci/R&D Officer | |
Evox Therapeutics Ltd.
 Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member | |
Casebia Therapeutics LLC
 Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Casebia Therapeutics LLC is a joint venture company that focuses on discovering, developing, and commercializing gene-editing therapeutics to treat genetic causes of bleeding disorders and autoimmune diseases. The company is based in Cambridge, MA. | Pharmaceuticals: Generic | Corporate Officer/Principal | |
| ORCHARD THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
| Royal Free Hospital Medical School | College/University | Corporate Officer/Principal | |
Auregen Biotherapeutics, Inc.
 Auregen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auregen Biotherapeutics, Inc. provides biotechnology services. The CEO of the American company is Richard John Davies. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
Exo Therapeutics, Inc.
 Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director of Finance/CFO | |
Freeline Therapeutics GmbH
 Freeline Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Ascend Gene & Cell Therapies Ltd., Freeline Therapeutics GmbH is a German biotechnology company that focuses on liver directed gene therapies for bleeding disorders and other chronic diseases. The private company is based in Planegg, Germany. The company has a pipeline of gene therapies that have the potential to change the lives of people with chronic, debilitating diseases. Freeline has two key enabling platforms critical to realizing AAV gene therapy across its indications\: its proprietary AAV vector platform and its high-performing manufacturing platform. The company was founded in 2015, and the CEOs are Markus Hörer and Karl Christian Heller. Freeline Therapeutics was acquired by Ascend Gene & Cell Therapies Ltd. from Freeline Therapeutics Holdings Plc on February 10, 2023 for $25.83 million. | Miscellaneous Commercial Services | Chief Executive Officer | |
| New Context Ltd. | Director/Board Member | ||
| ADICET BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
Novalgen Ltd.
 Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Biotechnology | Founder |
Statistiques
Internationale
| Etats-Unis | 34 |
| Royaume-Uni | 13 |
| Danemark | 4 |
| Suisse | 2 |
| Allemagne | 2 |
Sectorielle
| Health Technology | 22 |
| Consumer Services | 18 |
| Commercial Services | 8 |
| Technology Services | 3 |
| Health Services | 2 |
Opérationnelle
| Director/Board Member | 46 |
| Corporate Officer/Principal | 27 |
| Independent Dir/Board Member | 17 |
| Chief Tech/Sci/R&D Officer | 13 |
| Undergraduate Degree | 12 |
Relations les plus connectées
| Insiders | |
|---|---|
| Julia Gregory | 22 |
| Chris Hollowood | 19 |
| Jeffrey Chodakewitz | 15 |
| Colin Love | 11 |
| Michael Parini | 8 |
| Amit Chunilal Nathwani | 7 |
| Martin Andrews | 7 |
| Pamela Foulds | 6 |
| Stephen P. Diamond | 5 |
| James Bircher | 4 |
| Henning R. Stennicke | 4 |
| Paul Schneider | 4 |
| Benjamin Warriner | 3 |
| Nicole Jones | 3 |
| Markus Hörer | 2 |
- Bourse
- Insiders
- Amy J. Spandau
- Connexions Sociétés
